April 12, 2019 10:02 AM EDT
Peer Review

Peer Re­view: Leav­ing Cere­cor af­ter a year, Pe­ter Green­leaf starts a new CEO chap­ter at Au­rinia — out to slay Resta­sis

Amber Tong

→ A year af­ter or­ches­trat­ing Su­cam­po Phar­ma’s sale to Mallinck­rodt, Pe­ter Green­leaf is still in hot de­mand …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times